Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

ABSTRACT:

Background

RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other thyroid cancers. In patients with RET-altered thyroid cancers, the efficacy and safety of selective RET inhibition are unknown.

Methods

We enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandetanib or cabozantinib treatment, as well as those with previously treated RET fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response), as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety.

Results

In the first 55 consecuti

SUBMITTER: Wirth LJ 

PROVIDER: S-EPMC10777663 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature